Compare JPMorgan Chase & Co (JPM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Recursion Pharmaceuticals Inc — how do they compare? JPMorgan Chase & Co trades at $331.5 (market cap $880.98B), while Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B). The key difference: JPMorgan Chase & Co is far larger — about 411.7× Recursion Pharmaceuticals Inc's market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| JPM | RXRX | |
|---|---|---|
Market Cap | $880.98B | $2.14B |
Volume | 7,721,661 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $365.18 | $6.79 |
52-Week Low | $282.84 | $2.84 |
Typical Hold Time | 127 Days | 22 Days |
Enterprise Value | $1.82T | $1.66B |
Dividend Yield | 1.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $329.58, down 0.51% with a bearish technical signal. The stock shows strong fundamentals with revenue growth from $181.85B in 2025 to $194.9B projected for 2026, and a net income margin of 33.38%. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus remains positive with a $373.18 price target. However, negative cash flow trends and geopolitical risks noted by CEO Jamie Dimon present headwinds.
Outlook: JPM offers solid value with a P/E of 14.2 and high ROE of 18.43%, supported by earnings beats and institutional buying. Risks include sustained negative operating cash flow, rising debt-to-asset ratio (11.34% in 2024), and macroeconomic volatility. The stock is a hold for long-term investors, with upside to consensus target if earnings momentum continues.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
